How Long to Hold a DOAC Before a Procedure
For most elective procedures, hold DOACs for 1 day (24 hours) before low-to-moderate bleeding risk procedures and 2 days (48 hours) before high bleeding risk procedures, with longer interruption times required for dabigatran in patients with impaired renal function. 1
Risk Stratification of Procedures
The duration of DOAC interruption depends critically on the bleeding risk of the planned procedure:
- Minimal bleeding risk procedures (minor dental work, skin biopsies, cataract surgery) may be performed without interrupting DOACs or with holding only on the day of the procedure 2, 3
- Low-to-moderate bleeding risk procedures (cholecystectomy, inguinal hernia repair, colonoscopy with biopsy) require 1 day of interruption 1, 4
- High bleeding risk procedures (major cancer surgery, joint replacement, intracranial neurosurgery, neuraxial anesthesia) require 2 days of interruption 1, 4
Specific DOAC Interruption Protocols
For Apixaban, Rivaroxaban, and Edoxaban (Factor Xa Inhibitors)
Low-to-moderate bleeding risk procedures:
- Hold for 24 hours (skip 1-2 doses depending on dosing frequency) before the procedure 5, 1, 2
- Last dose should be taken 2 days before the procedure if once-daily evening dosing, or the morning of the day before if twice-daily or once-daily morning dosing 5
High bleeding risk procedures:
- Hold for 48 hours (skip 2-4 doses depending on dosing frequency) before the procedure 5, 1, 2
- For patients with CrCl 15-29 mL/min on rivaroxaban, extend to 3-4 days 6
Very high bleeding risk procedures (intracranial neurosurgery, neuraxial anesthesia):
- Hold for up to 5 days to ensure minimal residual anticoagulant effect 5
For Dabigatran (Direct Thrombin Inhibitor)
Dabigatran requires longer interruption times due to its predominant renal clearance (75-80% renal elimination) 1:
Low-to-moderate bleeding risk procedures:
- Normal renal function (CrCl ≥80 mL/min): Hold for 24 hours (skip 2 doses) 6, 2
- Mild renal impairment (CrCl 50-79 mL/min): Hold for 36 hours (skip 3 doses) 2
- Moderate renal impairment (CrCl 30-50 mL/min): Hold for 48 hours (skip 4 doses) 6, 5, 2
High bleeding risk procedures:
- Normal renal function (CrCl ≥80 mL/min): Hold for 48 hours (skip 4 doses) 6, 2
- Mild renal impairment (CrCl 50-79 mL/min): Hold for 72 hours (skip 6 doses) 2
- Moderate renal impairment (CrCl 30-50 mL/min): Hold for 96 hours (4-5 days, skip 8 doses) 6, 5, 2
Very high bleeding risk procedures:
- Hold for up to 5 days regardless of renal function 5
Critical Considerations
Renal Function Assessment
- Always calculate creatinine clearance using the Cockcroft-Gault formula before determining interruption timing 5
- Patients with severely impaired renal function (CrCl <30 mL/min) may require additional days of interruption beyond standard protocols 1
- Recent creatinine levels must be available; do not rely on outdated values 5
Drug Interactions
Extend interruption times for patients taking medications that interfere with DOAC clearance 5, 1:
- P-glycoprotein inhibitors (affect all DOACs, especially dabigatran)
- CYP3A4 inhibitors (affect factor Xa inhibitors: apixaban, rivaroxaban, edoxaban)
Age Considerations
- Patients ≥80 years old on dabigatran require special caution and may need longer interruption times, particularly for neuraxial procedures 5
- Elderly patients are at higher risk for residual DOAC levels even with standard interruption protocols 7
Common Pitfalls to Avoid
Do not use heparin bridging when interrupting DOACs for elective procedures 5, 1. Bridging increases bleeding risk without reducing thrombotic risk and is not recommended for DOAC interruption 5.
Do not routinely measure DOAC levels before elective procedures 5, 1. The standardized interruption protocol based on half-lives is sufficient for most patients. DOAC level measurement may be considered only for urgent/emergent procedures or very high-risk surgeries 5, 1.
Do not perform neuraxial anesthesia (spinal or epidural) in patients with possible residual DOAC concentrations, especially in elderly patients on dabigatran or those with renal impairment 5. The risk of epidural hematoma is catastrophic.
Do not assume all DOACs are equivalent in their interruption requirements. Dabigatran's renal clearance necessitates significantly longer hold times in patients with impaired kidney function compared to factor Xa inhibitors 6, 5, 1.
Resumption of DOACs After Procedures
- Low bleeding risk procedures: Resume at full dose 24 hours (1 day) after the procedure 1, 4
- High bleeding risk procedures: Resume at full dose 48-72 hours (2-3 days) after the procedure once adequate hemostasis is achieved 5, 1, 4
- Resume at least 6 hours after minor procedures if hemostasis is secure 5
- If ongoing bleeding or surgical contraindication exists, delay resumption and consider pharmacologic or mechanical thromboprophylaxis 5
Evidence Quality
The 2022 American College of Chest Physicians guideline provides the most recent high-quality evidence supporting this standardized approach 1. The French Working Group on Perioperative Hemostasis (2017) offers concordant recommendations with additional granularity for specific clinical scenarios 5. The PAUSE study and subsequent analyses demonstrate that this pharmacokinetic-based approach results in low rates of thromboembolism (0.2-0.4%) and major bleeding (1-2%) 1, 4.